Myoferlin, a member of ferlin family of proteins, was first discovered as a candidate gene for muscular dystrophy and cardiomyopathy. Recently, myoferlin was shown to be also expressed in endothelial and cancer cells where it was shown to modulate vascular endothelial growth factor (VEGFR)-2 and epidermal growth factor receptor (EGFR) signaling by enhancing their stability and recycling. Based on these reports, we hypothesized that myoferlin might be regulating IL-6 signaling by modulating IL-6R stabilization and recycling. However, in our immunoprecipitation (IP) experiments, we did not observe myoferlin binding with IL-6R. Instead, we made a novel discovery that in resting cells myoferlin was bound to EHD2 protein and when cells were treated with IL-6, myoferlin dissociated from EHD2 and binds to activated STAT3. Interestingly, myoferlin depletion did not affect STAT3 phosphorylation, but completely blocked STAT3 translocation to nucleus. In addition, inhibition of STAT3 phosphorylation by phosphorylation-defective STAT3 mutants or JAK inhibitor blocked STAT3 binding to myoferlin and nuclear translocation. Myoferlin knockdown significantly decreased IL-6-mediated tumor cell migration, tumorsphere formation and ALDH-positive cancer stem cell population, in vitro. Furthermore, myoferlin knockdown significantly decreased IL-6-meditated tumor growth and tumor metastasis. Based on these results, we have proposed a novel model for the role of myoferlin in chaperoning phosphorylated STAT3 to the nucleus.
INTRODUCTION IL-6, a pleiotropic cytokine, is involved in a number of cellular processes including, cell proliferation, cell motility, cell survival and immune response. [1] [2] [3] [4] IL-6 is one of the main chemokines present in serum samples of cancer patients and elevated IL-6 levels have also been shown to be an independent predictor of poor survival, tumor recurrence and tumor metastasis in a number of malignancies including breast, prostate and head and neck cancers. [5] [6] [7] [8] Recently, we have shown that IL-6 promotes tumor metastasis by inducing epithelial-mesenchymal transition. 2 IL-6 mediates its biological function predominantly through binding to IL-6Rα (IL-6 receptor-α) on the cell surface. 9 IL-6 binding to its receptor in turn induces conformational changes leading to the formation of IL-6/IL-6Rα/gp130 hexameric complex (a gp130 homodimer plus IL-6/IL-6Rα hetrodimers). [10] [11] [12] This complex then recruits Janus (JAK) kinases and phosphorylates them. 13 Activated JAKs, phosphorylate cytosolic STAT3, which then translocates to the nucleus to function as a transcription factor. 14 This nuclear translocation of activated STAT3 is critical for the IL-6/STAT3 signaling. But, protein shuttling across nuclear membrane is tightly regulated 15 and very little is known about the molecular events that facilitate the nuclear translocation of STAT3. In this study, we observed that phosphorylation of STAT3 by IL-6 leads to its binding with myoferlin and co-migration to the nucleus. Although myoferlin has been shown to regulate cell membrane fusion, repair and recycling, 16, 17 there are no studies that have investigated the role of myoferlin in IL-6/STAT3 signaling particularly its role in chaperoning STAT3 to the nucleus.
Myoferlin, a member of the ferlin family of proteins, was originally discovered as a muscle-specific protein. 18 The ferlin family of proteins share similar domain architecture that includes a carboxy-terminal transmembrane domain and multiple aminoterminal C2 domains, which promote their binding to negatively charged phospholipids. [19] [20] [21] The ferlin family of proteins (dysferlin, otoferlin and myoferlin) has been extensively studied in muscle cell function and it has been shown to play an important role in plasma membrane integrity, myoblast fusion and vesicle trafficking. 18, [22] [23] [24] Mutations of dysferlin are linked to limb girdle muscular dystrophy type B and Myoshi myopathy because skeletal muscle fiber sarcolemma in these patients fail to repair damaged muscle cells, 21 whereas mutations of otoferlin leads to nonsyndromic deafness because synaptic vesicles fail to fuse at the plasma membrane. 25 Myoferlin is a 230-kDa protein that is highly expressed in myoblasts 18, 26 and myoferlin depletion studies in mice showed strong muscular dystrophy due to the failure of myoblasts to fuse and form large multinucleate myotubes. 23 Recently, a number of different groups have shown that myoferlin is also expressed in endothelial and cancer cells. 17, [27] [28] [29] [30] [31] Bernatchez et al. 17 have shown that myoferlin modulates vascular endothelial growth factor /vascular endothelial growth factor receptor (VEGF/ VEGFR-2) signaling in vascular endothelial cells by stabilizing VEGFR-2. Myoferlin depletion in endothelial cells also significantly decreased angiogenic tyrosine kinase receptor (Tie-2) expression. 32 In cancer cells, myoferlin was shown to regulate epidermal growth factor/epidermal growth factor receptor (EGF/ EGFR) signaling by stabilizing EGFR. 27 In this study, we observed that in the resting cancer cells myoferlin is bound to EHD2 protein and when the cancer cells are treated with IL-6, myoferlin dissociates from EHD2, binds to activated STAT3 and chaperone it to nucleus to mediate its transcriptional role. Myoferlin depletion in the cancer cells significantly decreased tumor cell migration and tumorsphere formation, in vitro and tumor progression, in vivo. Taken together, our results from this study provide a novel oncogenic role for myoferlin in modulating IL-6/STAT3 signaling that plays an important function in a number of cellular processes including cell proliferation, cell migration and cancer stem cell phenotype. [2] [3] [4] 
RESULTS

Myoferlin expression is significantly upregulated in tumor samples from head and neck squamous cell carcinoma (HNSCC) patients and HNSCC cell lines
We have recently shown by immunohistochemistry (IHC) that myoferlin expression is markedly upregulated in HNSCC and it directly correlates with poor overall survival. 33 In this study, we measured myoferlin expression levels in 30 frozen samples from HNSCC patients (20 primary tumors and 10 adjacent normal controls) by real-time PCR. Our results show that myoferlin expression was significantly higher in HNSCC tumor samples (Mann-Whitney test; P-value 0.0008) as compared with adjacent normal tissue ( Figure 1a ). We next examined whether myoferlin expression is also higher in head and neck tumor cell lines as compared to normal epithelial cells. Indeed, both myoferlin mRNA and protein levels were significantly higher in head and neck cancer cell lines as compared with normal epithelial cells (Figures 1b and c) .
IL-6 induces STAT3-myoferlin binding and co-migration to nucleus
We and others have previously shown that IL-6 activates a number of different pathways including JAK/STAT3 pathway (Figure 2a ). 2, 4 Recently, myoferlin was shown to bind to VEGFR-2 and promote its stability and recycling. 17 We initially examined if myoferlin might be modulating IL-6 signaling by regulating IL-6 receptor (IL-6R) stability and recycling. However, our immunoprecipitation (IP) and HA pull-down experiments suggest that myoferlin does not bind to IL-6R (data not shown). Instead, we observed that in resting cells myoferlin is bound to EHD2 protein and upon stimulation with IL-6, myoferlin dissociates from EHD2 and binds to activated STAT3 (Figures 2b and d ). STAT3 is cytoplasmic protein that is predominantly activated at the cell surface and then migrates to nucleus to function as a transcription factor. 34 We next examined if myoferlin binding to phosphorylated STAT3 affected its translocation to nucleus. IL-6 treatment of CAL27 cells induced a time-dependent co-migration of myoferlin and STAT3 to nucleus (Figures 3a and b ). We next examined if this IL-6induced co-migration of myoferlin and STAT3 is also observed in other HNSCC cell lines. We repeated these experiments using another HNSCC cell line (UM-SCC-74B) and we observed a similar co-migration of myoferlin and STAT3 to nucleus (Figure 3c and Supplementary Figure 1a ). Recent studies have shown that myoferlin expression is also elevated in breast cancer cells and it promotes cancer cell motility, invasion and epithelial to mesenchymal transition. 27, 35 We next examined if myoferlin and STAT3 comigrated to nucleus in response to IL-6 treatment in breast cancer cells. Indeed, IL-6 treatment of breast cancer cells (MDA-MB-231) induced co-migration of myoferlin and STAT3 to nucleus (Figure 3d and Supplementary Figure 1b ). We next knocked down myoferlin in tumor cells by siRNA and examined if myoferlin regulates IL-6-induced STAT3 phosphorylation and nuclear translocation. Our results show that myoferlin knockdown does not affect IL-6-mediated STAT3 phosphorylation ( Figure 3e ) but myoferlin knockdown significantly blocked STAT3 translocation to nucleus (Figure 3f and Supplementary Figure 2 ). STAT3 phosphorylation is required for STAT3 binding to myoferlin and translocation to nucleus We next examined if STAT3 phosphorylation is required for myoferlin binding and translocation to nucleus. To answer this question, we employed two different approaches. In the first set of experiments, we used a JAK inhibitor (JAK inhibitor 1) to block STAT3 phosphorylation and examined myoferlin binding to STAT3 and translocation to nucleus. Our result show that JAK inh-1 markedly reduced IL-6-mediated STAT3 phosphorylation (Figure 4a ), myoferlin binding to STAT3 ( Figure 4b ) and nuclear translocation of STAT3 and myoferlin (Figure 4c ). In the second set of experiments, we overexpressed STAT3 phosphorylationdefective mutant (STAT3YF, kindly provided by Dr Tom Smithgal, University of Pittsburgh) with a Tyr-705 to Phe-705 substitution. 36 Tumor cells overexpressing STAT3YF mutant showed marked decrease in IL-6-mediated STAT3 phosphorylation (Figure 4d ), myoferlin binding to STAT3 ( Figure 4e ) and nuclear translocation of STAT3 and myoferlin ( Figure 4f ). These results therefore suggest that STAT3 phosphorylation at Tyr-705 is critical for myoferlin binding and nuclear translocation.
Myoferlin knockdown significantly decreases tumor cell migration, tumorsphere formation and ALDH-positive tumor cells IL-6/STAT3 signaling has been shown to promote tumor cell motility and stem cell phenotype. 2, 37 We next examined if myoferlin knockdown affects IL-6-mediated tumor cell migration and cancer stem cell phenotype. To stably knockdown myoferlin, we used two different shRNAs (shRNA1 purchased from Sigma (St Louis, MO, USA) and shRNA2 from Santa Cruz, (Dallas, TX, USA)). Cells transduced with scrambled shRNA were used as control ( Figure 5a ). Our results show that myoferlin knockdown using both shRNAs significantly decreased IL-6-mediated tumor cell motility (Figure 5b ). Myoferlin knockdown also significantly decreased ALDH-positive cells in IL-6 overexpressing CAL27 cells ( Figure 5c ) and tumorsphere formation in CAL27-IL-6 cells (Figures 5d and e ). Similarly, myoferlin knockdown in UM-SCC-74A cells (HNSCC cell line that naturally express high levels of IL-6) significantly decreased tumor cell migration and tumorsphere formation (data not shown). In addition, myoferlin knockdown significantly decreased the expression of IL-6/STAT3 target genes (snail and nanog) in UM-SCC-74A cells (Figure 5f ).
Myoferlin knockdown significantly decreases tumor growth and tumor metastasis, in vivo
We had previously shown that IL-6-STAT3 pathway is critical for tumor metastasis. 2 To further examine the role of myoferlin in IL-6-STAT3 signaling pathway and tumor metastasis, we stably knocked down myoferlin in CAL27-IL-6 or UM-SCC-74A (a highly metastatic HNSCC cell line that naturally expresses high levels of IL-6) 38 cells by 2 shRNAs. Our in vitro biochemical and functional experiments suggest that both these shRNAs were effective in blocking myoferlin expression and function. In our in vivo experiments, we used cells that were transduced by myoferlin shRNA purchased from Sigma-Aldrich. Cells transduced with scrambled shRNA were used as control. IL-6 overexpression in CAL27 cells significantly increased tumor growth as compared with CAL27 cells transduced with vector alone (CAL27-VC) ( Figure 6a ). In addition, CAL27-IL-6 tumors showed markedly higher expression of nanog ( Supplementary Figure 3a Lymph nodes from animals carrying CAL27-VC tumors were negative for metastatic disease whereas 55% of lymph nodes from animals carrying CAL27-IL-6 tumors were positive for metastatic disease (Figure 6e ). Myoferlin knockdown in CAL27-IL-6 cells (CAL27-IL-6-MYOF KD) significantly decreased in lymph node metastatic disease ( Figure 6e ). In addition, lungs from animals carrying CAL27-IL-6-MYOF KD tumors showed significant decrease in metastatic nodes (Figure 6f ). Similarly, myoferlin knockdown in UM-SCC-74A cells significantly deceased lymph node (Figure 6g ) and lung metastasis (Figure 6h ).
Proposed mechanism of myoferlin role in IL-6/STAT3 signaling Based on the results from this study, we propose a novel mechanism by which myoferlin modulates IL-6/STAT3 signaling ( Figure 7 ). In the resting state, myoferlin is bound to EHD2 protein ( Figure 7a ). IL-6 binding to IL-6R induces STAT3 phosphorylation ( Figure 7b ) and also leads to myoferlin dissociation from EHD2 and binding to phosphorylated STAT3 and chaperoning pSTAT3 to nucleus (Figure 7c ). In the nucleus, STAT3 functions as a transcription factor and regulates a number of IL-6/STAT3 downstream genes including snail and nanog.
DISCUSSION
In this study, we demonstrate that a muscle-specific protein 'myoferlin', which is absent or expressed at very low levels in normal mucosa is markedly upregulated in head and neck cancer cells. Recent studies have shown a similar elevated expression of myoferlin in breast, lung and pancreatic cancer cells. 27, [29] [30] [31] All the previously published studies in muscle, endothelial cells and cancer cells have thus far examined the role of myoferlin in plasma membrane function particularly membrane repair, vesicle trafficking and receptor stability. 16, 17, 22, 23, 27 Based on these studies, we initially hypothesized that myoferlin might be regulating IL-6 signaling by modulating IL-6R recycling and stability. However, we did not observe myoferlin binding to IL-6R and its recycling to plasma membrane. Instead, we observed that myoferlin binds to activated STAT3 and co-migrates to nucleus. Myoferlin has been previously shown to be present in the nucleus of muscle cells. 18 Recently, we examined sub-cellular expression of myoferlin in tumor samples from HNSCC patients.
We observed that nuclear myoferlin expression is highly predictive of poor overall survival (P o 0.0001) and patients whose tumors were nuclear myoferlin positive had 5.4 times the hazard of death than patients whose tumors had myoferlin present in cytosol or at plasma membrane (95% confidence interval: 3.4-8.8). 33 There is no published study so far that has examined the functional role of myoferlin in the nucleus. Therefore, in this study, we examined if myoferlin modulates IL-6/STAT3 signaling by binding to phosphorylated STAT3 and chaperoning it to the nucleus. In our IP and HA pull-down experiments, we observed that myoferlin is bound to EHD2 protein in resting cells and IL-6 treatment of these cells induced myoferlin dissociation from EHD2 and binding to phosphorylated STAT3. EHD2 protein is predominantly studied for its role in endocytic recycling and has been shown to bind to myoferlin in muscle cells. 24 It is possible that EHD2 protein might also function as a natural inhibitor of myoferlin by binding to it and blocking its IL-6/STAT3 signaling functions. Recent studies have shown that EHD2 could function as a tumor suppresser protein. [39] [40] [41] [42] EHD2 overexpression was inversely associated with overall survival and EHD2 knockdown significantly enhanced breast cancer and esophageal squamous cell carcinoma cell migration, cell invasion and enhanced epithelial to mesenchymal transition. 39, 40 In this study, we observed that dissociation of EHD2 from myoferlin in activated tumor cells (treated with IL-6) led to enhanced tumor cell motility and cancer stem cell phenotype. Similarly, myoferlin knockdown in cancer cells significantly inhibited tumor cell motility, tumor invasion and promoted mesenchymal to epithelial transition. 35, 43 These results support our inference that EHD2 might mediate its tumor suppressor function by inhibiting myoferlin function and IL-6/STAT3 signaling. However, further studies are required to validate the role of EHD2 in negatively regulating myoferlin function.
There have been contradicting reports regarding the requirement of tyrosine phosphorylation in STAT3 protein for its translocation to the nucleus. [44] [45] [46] Liu et al. 44 have recently shown that STAT3 nuclear import is independent of tyrosine phosphorylation. However, a number of other studies have shown that tyrosine phosphorylation (particularly mediated by growth factors; for example, IL-6, VEGF) is required for STAT3 translocation to the nucleus. 45, 46 Our results suggest that in IL-6 mediated STAT3 nuclear translocation, tyrosine phosphorylation is essential for its binding to myoferlin and subsequent translocation to nucleus. However, in myoferlin-deficient cells, STAT3 tyrosine phosphorylation alone was not enough to mediate its translocation to nucleus. It is possible that at basal level, STAT3 nuclear translocation might not be dependent on tyrosine phosphorylation and is predominantly mediated by binding to importin-a3. 44 But in the growth factor (for example, IL-6) mediated nuclear translocation, STAT3 phosphorylation markedly upregulates its nuclear translocation by enhancing STAT3 binding to a chaperone protein 'myoferlin'. Similar chaperones mediated enhanced nuclear trafficking of glucocorticoid receptors have been reported. 47 Recently, we have shown that high expression of IL-6 is directly associated with nuclear localization of myoferlin in head and neck tumors. 33 In addition, nuclear myoferlin expression was predictive of tumor recurrence, perineural invasion, extracapsular spread and distal metastasis. Similarly, a number of gene microarray studies have reported an association between myoferlin expression and metastatic cancer. [48] [49] [50] However, molecular mechanism(s) that underline myoferlin-mediated aggressive and metastatic phenotype in cancer cells is not very well understood. Our results from this study provide a novel insight into the role of myoferlin in regulating IL-6/STAT3 signaling cascade that has been shown to promote tumor growth, chemoresistance and tumor metastasis, 2, 51, 52 Results from this study also provide a scientific rationale to design small molecule inhibitors that could disrupt myoferlin/STAT3 protein-protein interactions thereby providing a novel therapeutic option for the treatment of head and neck cancer patients.
MATERIALS AND METHODS
Patient tumor samples, reagents and cell lines
Tumor and normal tissue samples used in this study were collected from HNSCC patients undergoing treatment at the James Cancer Hospital after obtaining informed consent. The use of patient samples was approved by the Ohio State University institutional review board. CAL27 and MDA-MB-231 were obtained from ATCC (Manassas, VA, USA). UM-SCC-74A and UM-SCC-74B cell lines were obtained from the laboratory of Dr Thomas E Carey at the University of Michigan. 53 The identity of all the tumor cell lines was confirmed by STR genotyping (Identifiler Kit, Applied Biosystems, Carlsband, CA, USA). Immortalized (HPV E6/E7) oral epithelial cells were kindly provided by Drs William Foulkes and Ala-Eddin Al Moustafa (McGill University, Montreal, QC, Canada). 54 Normal human oral keratinocytes were obtained from ScienCell (Carlsbad, CA, USA). All tumor cell lines were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum containing 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) and 1% Non-essential amino acids. Immortalized oral epithelial cells and human oral keratinocytes were grown in keratinocyte growth medium (Invitrogen). HA-tagged myoferlin plasmid (pCDNA3. 
Quantitative PCR
RNA from the tumor samples (n = 20), normal controls (n = 10), HNSCC cell lines (n = 10) and normal epithelial cells (n = 2) was extracted using TRIzol reagent (Invitrogen). Myoferlin, snail or nanog RNA was transcribed into cDNA and amplified with TaqMan primer/probes (myoferlin; Hs00203853-m1, nanog; Hs02387400-g1 and snail; Hs00195591-m1). mRNA expression for myoferlin, snail or nanog was normalized to OAZ1 using the 2 -ΔΔCt method. 55 Myoferlin overexpression HA-tagged myoferlin was transfected in immortalized oral epithelial cells using lipofectamine 3000 (Invitrogen). 2 Myoferlin overexpression was verified by western blotting.
Myoferlin knockdown with siRNA or shRNA CAL27 and UM-SCC-74A cells were transduced with Dharmacon siGENOME SMART pool siRNA for Myoferlin. In brief, tumor cells were cultured in 60 mm dishes and transfected with 100 nM of siRNA SMART pool. Cells transfected with scrambled siRNA were used as control. After 16-18 h of incubation, cells were washed with PBS and further incubated in fresh medium. Seventy-two hours post transfection, cells were used for experiments. For stable knockdown, we used two shRNAs; MISSION Myoferlin shRNA Lentiviral transduction particles from Sigma-Aldrich and Myoferlin shRNA (m) Lentiviral particles from Santa Cruz Biotechnology. MISSION pLKO.1-puro carrying scrambled shRNA was used as a control. The lentiviral constructs were transduced in the cells in 96-well plate using polybrene to the final concentration of 4 μg/ml. The transfected cells were selected with puromycin treatment and myoferlin knockdown was confirmed by western blotting.
Immunoprecipitation
Tumor cells were cultured in 6 cm dishes and treated with IL-6. After 30 min, cells were washed with PBS and whole-cell lysate prepared. The whole-cell lysate was then incubated with 50 μl of protein A/G agarose beads (Thermo Scientific-Pierce, Rockford, IL, USA) for 30 min at 4°C. After pre-clearing step, cell lysate was incubated with anti-myoferlin antibody overnight at 4°C on rocker. Next, protein A/G Agarose beads slurry was added to the cell lysate and further incubated for 4 h at 4°C. After incubation, agarose beads were collected by centrifuging the slurry. Proteins bound to agarose beads were separated by adding 2 × sample buffer and boiling it at 95°C for 5 min. 
Cytoplasmic and nuclear protein extraction
Nuclear and cytoplasmic proteins from tumor cells were separated using the NE-PER Nuclear & Cytoplasmic extraction kit (Pierce). Cells were treated with IL-6 for different time points and then harvested for cytosolic and nuclear protein extraction. Cell pellet was treated with cell membrane lysis reagents from the extraction kit to release the cytoplasmic contents. The cytoplasmic proteins were collected by centrifugation leaving the intact nuclei in the pellet. The nuclear pellet was washed with PBS to reduce carryover of the cytoplasmic proteins to the nuclear protein fraction. Nuclear lysis buffer was then added to the pellet to lyse the nuclei and release the nuclear proteins. Reducing agent and loading buffer were then added to the cytoplasmic and nuclear extracts and analyzed by western blotting.
Western blot analysis
Cell lysates were separated using NuPAGE gels (Invitrogen) and transferred onto PVDF membranes. Non-specific bindings were blocked by incubating membranes with 5% Milk or 3% bovine serum albumin in tris-buffered saline with tween 20 for 1 h at room temperature. Membranes were then incubated with the respective primary antibody in tris-buffered saline with tween 20+5% Milk or 3% bovine serum albumin at 4°C overnight. The blots were washed and then incubated with sheep anti-mouse (1:3000) or with donkey anti-rabbit (1:4000) IgG-labeled with horseradish peroxidase for 1 h at room temperature and specific protein bands were detected using ECL-plus kit (Thermo Scientific-Pierce). Equal protein loading was verified by stripping the blots and then reprobing it for GAPDH.
Immunofluorescent staining
Tumor cells were cultured in Labtech chambers and treated with recombinant IL-6 (50 ng/ml). At the end of incubation, cells were fixed with 4% paraformaldehyde and permeablized by treatment with 100% methanol for 10 min at − 20°C. Next, slides were washed with PBS, blocked with normal goat IgG for 1 h and incubated overnight at 4°C with rabbit anti-myoferlin and mouse anti-STAT3 antibodies. After three washes, chamber slides were then incubated with secondary antibodies (Alexa Fluor 488 labeled-goat anti-mouse-IgG or goat Alexa Fluor 594 labeledanti-rabbit-IgG). Chamber slides were then mounted with ProLong gold with DAPI (Invitrogen). The immunofluorescent staining images were captured using Nikon Eclipse 80i microscope and overlaid using NIS-Elements-Basic software (Nikon, Melville, NY, USA).
Tumor cell motility assay
We used Xcelligence system (ACEA Biosciences, San Diego, CA, USA) to measure tumor cell motility. 2 In brief, 160 μl of Dulbecco's Modified Eagle's media with 10% FBS was carefully added to the lower chambers. Next, upper chamber was then carefully assembled with lower chamber and 50 μl of serum free media added to the top wells. After 1 h, cell suspension (50 000 cells in 100 μl) was added to each well. Cell migration from upper chamber to lower chamber was monitored for 24 h.
ALDH staining
Tumor cells were cultured in 6 cm plates, trypsinized and adjusted to 1 × 10 6 cells/ml. Cell were then subdivided into control and test groups and stained for ALDH (Stemcell Technologies). After staining, cells were analyzed by flow cytometry.
Tumorsphere formation
Tumor cells were cultured on ultralow binding plates (Corning, Lowell, MA, USA) for 10 days as previously described. 56 At the end of incubation, number of tumorsphere 450 μm were counted. Tumorspheres were gently spun down, mixed with Matrigel and allowed to solidify at 37°C. Matrigel plugs were then fixed, paraffin embedded and processed for IHC. Tumorsphere sections were deparaffinized and standard heat induced antigen retrieval method was used as described before. 57 Slides were then washed with tris-buffered saline with tween 20, blocked with normal goat serum for 1 h, and then incubated with rabbit anti-E-cadherin and mouse anti-nanog antibodies. After overnight incubation, slides were washed with PBS and further incubated with secondary antibodies (Alexa Fluor 488 labeled-goat anti-mouse-IgG and Alexa Fluor 594 labeled-goat anti-rabbit-IgG-). Slides were then mounted with ProLong gold with DAPI (Invitrogen). The immunofluorescent staining images were captured using Nikon Eclipse 80i microscope and overlaid using NIS-Elements-Basic software.
Tumor growth and metastasis model
Animal studies were approved by The Ohio State University IACUC Animal ethic committee. Myoferlin was stably knocked down in CAL27-IL-6 (CAL27 overexpressing IL-6) and UM-SCC-74A cells (naturally express high IL-6). Tumor cells (1 × 10 6 ) were implanted subcutaneously in the flanks of SCID mice (n = 5 for each group). 38 Tumor volume was measured twice a week starting day 6 till the end of the study. After 39 days, animals were euthanized and tumors, regional lymph nodes, and lungs were harvested. To label and identify flank draining lymph nodes, 25 μl of 5% dye (Evans Blue, Sigma) was injected in the foot pads of animals 30 min before euthanizing. 58 Primary tumors, lymph nodes and lungs were fixed with paraformaldehyde and processed for IHC as described in tumorsphere formation.
Statistical analysis
We used a conservative Bonferroni correction method for the sample size calculations. Results are presented as mean ± s.e.m. Mann-Whitney test was used to examine the significance of myoferlin expression in patient samples. For rest of the in vitro and in vivo experiments, we used two-way analysis of variance and Student's t-test to analyze the data. The difference between different groups with P-value of o 0.05 was considered significant.
